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ARTICLE
Protein phosphatase 5 regulates titin
phosphorylation and function at a sarcomere-
associated mechanosensor complex in
cardiomyocytes
Judith Krysiak1, Andreas Unger1,2, Lisa Beckendorf1, Nazha Hamdani1, Marion von Frieling-Salewsky3,
Margaret M. Redfield4, Cris G. dos Remedios5, Farah Sheikh6, Ulrich Gergs 7, Peter Boknik8 &
Wolfgang A. Linke 3,9
Serine/threonine protein phosphatase 5 (PP5) is ubiquitously expressed in eukaryotic cells;
however, its function in cardiomyocytes is unknown. Under basal conditions, PP5 is auto-
inhibited, but enzymatic activity rises upon binding of specific factors, such as the chaperone
Hsp90. Here we show that PP5 binds and dephosphorylates the elastic N2B-unique sequence
(N2Bus) of titin in cardiomyocytes. Using various binding and phosphorylation tests, cell-
culture manipulation, and transgenic mouse hearts, we demonstrate that PP5 associates with
N2Bus in vitro and in sarcomeres and is antagonistic to several protein kinases, which
phosphorylate N2Bus and lower titin-based passive tension. PP5 is pathologically elevated
and likely contributes to hypo-phosphorylation of N2Bus in failing human hearts. Further-
more, Hsp90-activated PP5 interacts with components of a sarcomeric, N2Bus-associated,
mechanosensor complex, and blocks mitogen-activated protein-kinase signaling in this
complex. Our work establishes PP5 as a compartmentalized, well-controlled phosphatase in
cardiomyocytes, which regulates titin properties and kinase signaling at the myofilaments.
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During the lifetime of a beating heart, the cardiomyocytesmust respond dynamically to a multitude of internal andexternal stresses. Such functional flexibility is supported at
the level of the contractile units, the sarcomeres, by the expression
of cardiac-specific isoforms of structural, contractile, and reg-
ulatory proteins. Some of them, such as cardiac troponin-I,
myosin-binding protein-C, or titin, contain unique sequence
motifs that can be phosphorylated and dephosphorylated by
protein kinases and phosphatases, respectively. These selective
biochemical events then help to quickly adjust the mechanical
function of the cardiac sarcomere to altered physiological
requirements, e.g., during exercise. In the diseased heart this fine-
tuned mechanism can be disrupted. Whereas multiplex kinase
signaling has been recognized as an important modifier of cardiac
function at the level of sarcomeric proteins1, much less is known
about how this function is modulated by protein phosphatases2.
Titin is a multifunctional protein giant, which determines the
‘passive’ elasticity of the sarcomere3, 4 and also modulates active
contractile properties5–8. Human titin encompasses up to ~
36,000 amino acids encoded by the 364 exons of the TTN gene
and probably is the protein with the most (potential) phosphor-
ylation sites, but very few have been explored functionally3. Only
one region in titin, termed N2B (encoded by exon 49 in mouse
and human), is unique to the cardiac isoforms9. This region is
located in the elastic (I-band) segment of the molecule and
contains a 572-residue N2B-unique sequence (N2Bus), which is
an important spring element10. Moreover, N2Bus is a hub for
protein-protein interactions3 and a major site for oxidation11 and
phosphorylation12–15. Several protein kinases (PKs) phosphor-
ylate N2Bus, including PKA12, PKG13, the mitogen-activated
protein kinase (MAPK) extracellular signal-regulated kinase 2
(ERK2, encoded by MAPK1)14, and Ca2+/calmodulin-dependent
protein kinase IIδ (CaMKIIδ)15. Functionally, enhanced phos-
phorylation increases the distensibility of N2Bus and lessens the
force needed to stretch this spring element, which lowers cardi-
omyocyte passive tension3. Whether this phosphorylation affects
protein-protein interactions at N2Bus is unknown. Interestingly,
N2Bus shows a phosphorylation deficit in human and experi-
mental heart failure (HF), which contributes to increased myo-
cardial passive stiffness, notably in HF with preserved ejection
fraction (HFpEF)3.
In the present study, we identified serine/threonine protein
phosphatase 5 (PP5, encoded by PPP5C) as a novel interaction
partner of N2Bus and a physiological antagonist to the PKs that
phosphorylate N2Bus. PP5 is established as a ubiquitous enzyme
in eukaryotic cells involved in multiple signaling pathways
important for cell cycle progression, glucocorticoid receptor
activation, DNA damage repair, transcriptional activation, or
apoptosis16, 17. PP5 is unique among serine/threonine phospha-
tases as it contains a tetratricopeptide repeat (TPR) domain at the
N-terminus, which binds to the C-terminal catalytic domain and
blocks substrate access to the catalytic site, such that ‘free’ PP5
has low activity18, 19. However, PP5 becomes activated when the
autoinhibitory mechanism is released by interaction of the TPR
region with Ca2+/S100 proteins20 or heat-shock protein 90
(Hsp90)21,22. Activation is also possible through binding of
polyunsaturated fatty acids (e.g., arachidonic acid) or long chain
fatty acid-CoA esters (LCACE)23. Mice deficient in PP524 and
those overexpressing PP5 in the heart25 are viable and grow
normally, but do show some (more subtle) functional changes in
cell types such as fibroblasts24 or cardiomyocytes25. However,
little else is known about PP5 in the heart and nothing in human
cardiomyocytes.
An important function of PP5 is that of a negative feedback
regulator of MAPKs. PP5 inhibits the stress-activated protein
kinase JNK/p38 pathway by binding and dephosphorylating
apoptosis signal-regulating kinase-1 (ASK1, encoded by
MAP3K5) in response to oxidative stress26. Moreover, PP5
dephosphorylates Raf-1 and suppresses downstream signaling to
MAPK/ERK kinase (MEK, encoded by MAP2K) and ERK1
(MAPK3)/ERK2 (MAPK1)27. While PP5 also interacts with
ERK1/2, it does not dephosphorylate it28. The relationship
between PP5 and the MAPK/ERK branch is particularly inter-
esting in connection with titin, since Raf-1, MEK1 (MAP2K1)/
MEK2 (MAP2K2) and ERK2 are recruited to N2Bus via a linker,
four-and-a-half-LIM-domains protein-1 (FHL-1)29. The N2Bus-
FHL-1-MAPK complex forms a putative sarcomeric mechan-
osensor involved in pro-hypertrophic cardiac signaling29.
Whereas in vitro evidence suggested that FHL-1 blocks phos-
phorylation of N2Bus by ERK214, phosphorylation of cardiac
fibers by ERK2 readily lowered their titin-based passive tension30.
Here we show that PP5 dephosphorylates titin specifically at
N2Bus and reverses the effect of phosphorylation on titin-based
passive tension. Through association with Hsp90 and compo-
nents of the N2Bus-mechanosensor complex, PP5 operates in a
compartmentalized manner at the sarcomeric I-bands. Our work
establishes PP5 as a well-controlled enzyme in cardiomyocytes,
which regulates titin properties and MAPK signaling to support
dynamic heart function.
Results
PP5 binds the titin N2Bus domain. In a yeast-2-hybrid screen
(Y2H), we used full-length human titin N2Bus as bait and a
human adult heart cDNA library as prey. Approximately 150
clones grew on selective media plates and 50 of them were tested
positive in a β-galactosidase assay. Among the detected molecules
were FHL-2, which was previously identified as a binding partner
of N2Bus31, and the catalytic domain of PP5 (PP5c), specifically,
amino acids 205–266 of human PP5. The interaction with PP5
was verified in a direct Y2H binding assay using N2Bus as bait
and PP5c or full-length PP5 as prey (Fig. 1a). Analysis of diploid
clones by PCR revealed the expected inserts of 1.7 kb for N2Bus
and 1.5 or 1.0 kb for PP5 or PP5c, respectively. The N2Bus-PP5
interaction was also confirmed in vitro by GST-pulldown assays,
in which both full-length PP5 and PP5c interacted with N2Bus
(Fig. 1b). Two other I-band titin regions located near N2Bus,
PEVK and N2A, did not interact with PP5. To narrow down the
interaction site for N2Bus on PP5, we used two PP5 deletion
constructs in the GST-pulldown assays, the TPR region at the
PP5 N-terminus (‘T’-construct, residues 28–129) and the TPR
region with additional amino acids reaching into the catalytic
domain (‘T+’-construct, residues 28 to 211) (Fig. 1a). The T-
construct showed no interaction with N2Bus, whereas T+ did
(Fig. 1b), suggesting that the site of interaction involves the N-
terminal part of the catalytic domain. Taken together with the
Y2H binding data, it appears that amino acids 205–211 of PP5 are
critical for the interaction with N2Bus. These residues belong to
an α-helix exposed at the outer region of PP5 and are therefore
readily accessible19. The PP5-N2Bus binding was also probed by
co-immunoprecipitation in HEK cells. PP5-HA was coupled to
anti-HA agarose beads, N2Bus-myc-containing whole-cell lysate
was added and bound protein eluted for detection by western
blot. A weak but consistently reproducible interaction was
observed (Fig. 1c), confirming that PP5 is a novel interactor of
titin at the N2Bus.
PP5-binding to N2Bus is enhanced by phosphorylation of
N2Bus. To test if PP5c binds to titin in muscle sarcomeres, we
first used an assay on single isolated human cardiomyofibrils
placed under an inverted microscope and stretched under the
control of a piezo motor. Recombinant PP5c was added to the
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myofibril and binding detected by indirect immunofluorescence.
Consistent with the results of the co-immunoprecipitation assay
(Fig. 1c), exogenous PP5c bound only weakly to the myofibrils
(Fig. 1d, lower left images). However, the binding was much
intensified and clearly localized to the sarcomeric I-bands when
the myofibril was phosphorylated (by catalytic subunit of PKA)
prior to incubation with PP5c (Fig. 1d, lower right images). In
control experiments, neither Cy3-conjugated secondary antibody
alone (Fig. 1d, top) nor recombinant green fluorescence protein32
interacted with the myofibrils, suggesting that PP5 binding was
not due to a generally increased stickiness of stretched sarco-
meres. Considering the effect of prior phosphorylation of N2Bus
on PP5 binding, we performed GST-pulldown assays with
recombinant human PP5 and N2Bus, in which the latter was
phosphorylated by PKA catalytic subunit or cGMP-activated
PKG, or was left unphosphorylated (Fig. 1e). PP5 bound 2–3
times stronger to N2Bus if the titin region was phosphorylated
(Fig. 1e, bar graph). Furthermore, in a 162-residue C-terminal
fragment of N2Bus we mutated a known PKG-dependent phos-
phoserine at position 4185 (reference to full-length human
titin13) to alanine and used the wildtype (WT) and S4185A
N2Bus constructs, phosphorylated by cGMP-activated PKG, in
GST-pulldown assays with PP5. A small but significant decrease
in binding strength was found for the S4185A mutant (Fig. 1e),
providing further evidence that the PP5-N2Bus interaction is
enhanced by phosphorylation of N2Bus.
PP5 translocates to sarcomeres if induced in cardiomyocytes.
In testing for PP5 expression in vivo, we found a relatively high
level in embryonic (E18) and newborn (P1) rat hearts, which
decreased to half in adult rat hearts (Fig. 2a). We thus prepared
primary cultures of neonatal rat ventricular myocytes (NRVM)
and studied the intracellular localization of PP5 before and after
pharmacological manipulation using PP5-activator arachidonic
acid (aa; 200 µM) or potent inhibitor okadaic acid (oa; 10 nM)33.
Interestingly, PP5 activation by aa also increased the expression
level of PP5, compared to untreated NRVM, whereas PP5 inhi-
bition by oa decreased it (Fig. 2b). Confocal microscopy showed
PP5 to be distributed in a diffuse pattern all over the cytoplasm in
a
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Fig. 1 The elastic N2Bus domain of titin interacts with PP5. a Domain arrangement in the Z-disk/I-band region of cardiac titin N2B/N2BA isoforms and in
PP5. Constructs generated for yeast-two-hybrid (Y2H) screens marked in red, those for GST-pulldown assays in blue, and N2Bus-binding amino acids
(AA) of PP5 in green. Ig’s, immunoglobulin-like domains. Inset: Epitope positions of all phospho-titin antibodies used in this study. (m), anti-mouse; (h),
anti-human. b Summary of results of GST-pulldown assays probing interaction of N2Bus with full-length PP5, PP5 catalytic subunit (PP5c), or N-terminal
PP5 fragments (T; T+). PP5-binding to PEVK or N2A titin domains was also tested. GST, glutathione S transferase (for negative control). Each test was
performed a minimum of two times, mostly three times, with identical results. c Demonstration of PP5-N2Bus association by co-immunoprecipitation
assay. PP5 (HA-tag) immunoprecipitations (IP) and whole-cell lysates (WCL) from HEK cells analyzed by western blot for N2Bus (myc-tag) and PP5. PP5
-/+indicates absence/presence of PP5 in the assay. This test was performed three times, with identical results. d Binding of PP5 to sarcomeric I-bands is
enhanced by phosphorylation. Top: the experimental design for the stretching of single myofibrils and immunofluorescence image of stretched human
cardiac myofibril incubated in relaxing buffer with Cy3-conjugated secondary antibodies alone (control), as well as phase-contrast image (PC). Bottom:
representative images of myofibrils incubated with exogenous PP5c and stained against PP5c. The myofibril on the right was incubated with catalytic
subunit of PKA before PP5c-treatment (arrowheads, I-band localization of PP5). Binding visualized by anti-PP5c primary and Cy3-conjugated secondary
antibodies. Similar results were obtained from four other myofibrils per group. Bars, 2 µm. e Results of GST-pulldown assays probing interaction of PP5 with
unphosphorylated N2Bus or N2Bus phosphorylated by PKA/PKG, as well as wildtype (WT) and S4185A mutant of C-terminal N2Bus fragment, both
phosphorylated by cGMP-activated PKG. Left: representative immunoblots using anti-PP5 antibody. Right: relative signal intensities in ‘Bound’ lane,
normalized to the mean intensity of the respective non-phosphorylated/C-Term WT control. Data are mean± s.e.m., n= 4 assays/condition. *p< 0.05
and **p< 0.01, by two-tailed Student’s t-test
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control NRVM, with only an occasional hint at a more regular
striation pattern (Fig. 2c). However, stimulation by aa typically
caused some PP5 to translocate to the sarcomeric Z-disk/I-band
region, as suggested by co-localization with α-actinin (Fig. 2c;
note that due to the short sarcomere length (SL) of NRVM cul-
tures, the I-band and Z-disk regions are hardly distinguishable by
confocal microscopy). Treatment with oa always resulted in
PP5 staining patterns with no signs of regular striations. Because
PP5 negatively regulates MAPK signaling by dephosphorylating
Raf127, we also measured the expression and activity (phos-
phorylation) of the MAPK effector kinases ERK1/2 in NRVM.
Whereas ERK1/2 expression was unaltered by aa and oa treat-
ment, phospho-ERK1/2 was reduced by 65% in aa-treated cells
but little affected by oa, as compared to controls (Supplementary
Fig. 1a). Inhibitor of Raf1 (Raf1-I; 20 µM) lowered phospho-
ERK1/2 by ~ 50%. Even larger alterations in ERK1/2 activity were
seen in NRVM when the MAPK pathway was first stimulated by
angiotensin-2 (AngII) or endothelin-1 (ET-1), prior to treatment
with aa, oa, or Raf1-I (Supplementary Fig. 1b). Following ERK1/2
activation by AngII, treatment with oa now had an additional
stimulatory effect on phospho-ERK1/2. Taken together, these
findings suggest a link between PP5 and MAPK signaling, for the
first time also in cardiomyocytes.
We also studied PP5 localization in primary cultures of adult
rat cardiomyocytes (ARC) (Fig. 2d). Before PP5 induction, the
phosphatase was diffusely cytosolic in some cells, but appeared in
a regular striated (sarcomeric) pattern in others. Quantitation of
this distribution showed that the proportion of cells with regular
PP5 striations increased substantially in aa-treated (PP5-stimu-
lated) compared with control ARC (Fig. 2d, bar graph). In most
aa-stimulated cells, PP5 co-localized with the Z/I-region of the
sarcomere marked by α-actinin. Treatment with oa did not alter
the proportion of cells with regular PP5 striations, in comparison
to controls, and the diffuse PP5 distribution was seen more
frequently than in aa-treated cells (Fig. 2d). We conclude that,
particularly after induction in cardiomyocytes, PP5 is preferen-
tially translocated to the sarcomeres.
PP5 dephosphorylates titin at the N2Bus element. In order to
determine whether PP5 dephosphorylates titin, we first quantified
the total titin phosphorylation level in ARC cultures. Induction of
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*
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Fig. 2 Endogenous PP5 and phospho-titin in rat cardiomyocytes. a PP5 expression by western blot in fetal (E18), newborn (P1) and adult rat heart tissue.
PP5 indexed to GAPDH. Data are mean± s.e.m., n= 5; *p< 0.05, by two-tailed Student’s t-test. b PP5 expression by western blot in neonatal rat
ventricular myocyte (NRVM) cultures under baseline conditions (control) and following treatment with arachidonic acid (aa; 200 µM, 2 h) or okadaic acid
(oa, 10 nM, 1 h). PP5 indexed to GAPDH. Data are mean± s.e.m., n= 5 (three different cell culture batches); *p< 0.05 and **p< 0.01, by Bonferroni
adjusted t-test. c PP5 localization in control, aa-treated, and oa-treated NRVM cultures by indirect immunofluorescence. PP5 antibody (secondary
antibody: Cy3-conjugated IgG), counterstained with α-actinin antibody (secondary antibody: FITC-conjugated IgG). The merged image also shows staining
of nuclei using Hoechst. Bars, 10 µm. d PP5 localization in control, aa-treated, and oa-treated adult rat cardiomyocyte (ARC) cultures by indirect
immunofluorescence. The same antibodies as in c were used. Bars, 5 µm. Right bar graph shows proportion of ARC exhibiting clear PP5 striations or no
such striated pattern, for each group. Numbers above columns indicate total number of cells included in the analysis. e Total titin phosphorylation in the
three ARC groups measured by ProQ Diamond phosphoprotein vs. Sypro Ruby total protein stain. Bar graph shows mean± s.e.m., n= 9 (from three
independent cell preparations); *p< 0.05, by two-tailed Student’s t-test. f Localization of phosphoserine P-S3991 (titin N2Bus) in control, aa-treated, and
oa-treated ARC cultures by indirect immunofluorescence, using anti-N2BusP-S3991 antibody (secondary antibody: Cy3-conjugated IgG), counterstained
with α-actinin antibody (secondary antibody: FITC-conjugated IgG). Bars, 5 µm. Right bar graph shows proportion of ARC exhibiting clear N2BusP-S3991
striations or no such striated pattern, for each group. Numbers above columns indicate total number of cells included in the analysis
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PP5 by aa reduced titin phosphorylation by a small but
significant amount, whereas oa treatment did not alter it, in
comparison to non-treated control cells (Fig. 2e). Next we per-
formed indirect immunofluorescence on ARC using a phospho-
specific antibody against rat/mouse phosphoserine P-S3991
located in titin’s N2Bus element (equivalent to P-S4010 in
human titin15), which is known to be phosphorylated by ERK214
and PKA34. In most control cells, the N2BusP-S3991 epitope
appeared in a regular striation pattern, co-localizing with the Z/I-
region of the sarcomere marked by α-actinin (Fig. 2f). In PP5-
stimulated (aa-treated) ARC, the proportion of cells with regular
N2BusP-S3991 striations was reduced compared to controls,
whereas oa treatment did not alter this proportion (Fig. 2f, bar
graph). These results suggest that induction and translocation of
PP5 to the cardiac sarcomeres may result in dephosphorylation of
titin at N2Bus.
To substantiate this finding, we generated recombinant human
N2Bus and tested whether recombinant PP5 dephosphorylates
the construct after phosphorylation by a kinase. ERK2-
phosphorylated N2Bus was dephosphorylated by full-length
PP5 or (most effectively) by PP5c, which induced >90%
reduction of phosphorylation (Fig. 3a). In contrast, enzymatic
dead catalytic subunit of PP5 (PP5cH304A ED) was unable to
dephosphorylate the ERK2-phosphorylated N2Bus. Similar
experiments were conducted using PKA catalytic subunit or
cGMP-activated PKG as the phosphorylating kinases. Under
these conditions, PP5c dephosphorylated N2Bus by 45–50%,
whereas PP5c ED again showed no dephosphorylation effect
(Fig. 3b). These results, obtained using ProQ Diamond/Sypro
Ruby staining, were further validated in 32P-autoradiography
experiments, which showed that full-length PP5 and PP5c
dephosphorylated the PKG-phosphorylated N2Bus by ~55%
a
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Fig. 3 PP5 dephosphorylates recombinant and endogenous human N2Bus. a, b ProQ Diamond phosphoprotein vs. Sypro Ruby total protein stain of human
recombinant N2Bus phosphorylated (in presence of ATP) by ERK2 (a), catalytic subunit of PKA (b), or cGMP-activated PKG (b), and effect of human
recombinant full-length PP5, PP5 catalytic subunit (PP5c), or enzymatic dead (ED) PP5c mutant H304A on phosphorylation. ‘Control’ is recombinant
construct but no ATP/enzyme. n= 5. c 32P-ATP autoradiography using N2Bus phosphorylated by cGMP-activated PKG and dephosphorylated by PP5 or
PP5c. ‘No PK/PP’ is control in presence of 32P-ATP, but no enzyme. n= 4. dWestern blot (WB) of permeabilized human (donor) heart tissue treated with
various enzymes, as follows: alkaline phosphatase (AP), cGMP-activated PKG, then PP5 or PP5c. Detection of titin phosphorylation with phospho-specific
antibody to P-S4185 in human N2Bus. PVDF was coomassie-stained to reveal loading on gel. WB signals were normalized to PVDF signals. n= 4. e Site-
specific phosphorylation of residues within N2Bus and PEVK titin regions by western blot in myocardial tissue from human donor (Don) and end-stage
failing (Fail) hearts (n= 10/group). Detection with phospho-specific antibodies to P-S4010, P-S4099, P-S4185, P-S11878, and P-S12022 in the human titin
sequence. WB signals were normalized to PVDF signals. f Mean PP5 expression in human donor vs. end-stage failing hearts (n= 10/group). In a–f, bar
graphs show relative phosphorylation indexed to the respective phosphorylated controls. Data are mean± s.e.m.; *p< 0.05, **p< 0.01, and ***p< 0.001,
by two-tailed Student’s t-test or Holm-Sidak method
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and ~65%, respectively (Fig. 3c). The relatively high phosphatase
activity of full-length PP5 found in these experiments was
unexpected but consistently observed; it might be due to partial
cleavage (and thus, activation) of the phosphatase in vitro or
incomplete autoinhibition.
Recombinant full-length PP5 or PP5c also dephosphorylated
endogenous N2Bus in skinned (demembranated) human heart
tissue (Fig. 3d). Here, titin phosphorylation was detected by
western blot using phosphosite-specific antibodies to P-S4185, a
PKG/PKA-phosphorylated serine in human N2Bus13. Alkaline
phosphatase (AP) was used to initially dephosphorylate the heart
samples, before exogenous cGMP-activated PKG was given to
maximize N2Bus phosphorylation (=100% phosphorylation).
Subsequently, full-length PP5 or PP5c were able to depho-
sphorylate N2BusP-S4185 by 70% to 80% (Fig. 3d). These results
demonstrate that PP5 dephosphorylates N2Bus in vitro and in
heart tissue.
PP5 is increased in human and experimental heart failure. In
keeping with our earlier findings34,35, western blotting using
phospho-specific antibodies to human titin (for epitope positions,
see Fig. 1a) at residues P-S4010, P-S4099 (a PKG-dependent
phosphosite)34, and P-S4185 detected a phosphorylation deficit at
all three of these N2Bus sites in human end-stage failing hearts vs.
non-failing donor hearts, which amounted to ~25–50% (Fig. 3e).
In contrast, phosphorylation at P-11878 and P-12022 within the
titin PEVK element was unaltered in failing vs. donor hearts.
Interestingly, PP5 expression was ~45% higher in the failing
hearts (Fig. 3f). Furthermore, in hearts from elderly hypertensive
dogs with diastolic dysfunction, we observed ~30% less phos-
phorylation at N2Bus site P-S4010, compared to healthy canine
hearts (Supplementary Fig. 2a), whereas PP5 expression was
~60% higher in the diseased hearts (Supplementary Fig. 2b). We
conclude that hypo-phosphorylation of N2Bus in failing myo-
cardium from humans and animal models, which is known to
elevate titin-based passive stiffness3, may be attributable, at least
in part, to increased PP5-mediated dephosphorylation.
PP5 transgenic mouse hearts are hypo-phosphorylated at
N2Bus. The increase in PP5 expression observed in failing human
hearts prompted us to study titin phosphorylation in a transgenic
(TG) mouse model with cardiac-specific overexpression of PP5.
The cardiac phenotype of the TG model is mild, but some
impairment of cardiac contractility has been noted25. The PP5
protein level of the TG hearts was increased, on average by a
factor of 7–8, compared to that of matched WT hearts (Fig. 4a).
As expected due to the fact that PP5 dephosphorylates Raf1 at
S33827, phospho-Raf1S338 was significantly reduced in PP5 TG
hearts (Fig. 4a). Immunostaining against endogenous PP5 on
myocardial tissue sections demonstrated that the phosphatase was
present at low levels in WT cardiomyocytes and was distributed
in a diffuse cytoplasmic pattern, with an occasional sarcomeric I-
band localization (Fig. 4b, c). In PP5 TG myocytes, the phos-
phatase localized in a regular striated pattern to the I-bands near
the PEVK domain of titin and thus, the N2Bus position, as shown
by immunofluorescence (Fig. 4c) and immunoelectron micro-
scopy (Fig. 4b). Quantitation of the distribution of nanogold
particles on immunoelectron micrographs indicated the presence
of ~3 times more particles in PP5 TG than in WT hearts and
suggested that ~65% of total PP5 protein localized to the I-band
springs in PP5 TG cardiomyocytes, compared to ~30% in
WT cells (Fig. 4b, bar graph).
Total titin phosphorylation was measured by ProQ Diamond/
Sypro Ruby staining and a trend for reduced phosphorylation was
observed in PP5 TG vs. WT mouse hearts (Fig. 4d, upper left).
Site-specific phosphorylation was detected by western blot using a
panel of phosphoserine-specific antibodies against mouse titin
(for epitope positions, see Fig. 1a). Each phospho-specific
antibody was used together with a corresponding sequence-
specific antibody (Pan), which helped ascertain equal protein
loading. All three phosphoserines studied in N2Bus, P-S3991
(ERK2/PKA-dependent), P-S4043 (CaMKIIδ-dependent) and P-
S4080 (PKG-dependent), were significantly hypo-phosphorylated
(reduction, 45–50%) in PP5 TG vs. WT hearts (Fig. 4d, right
panels). In contrast, a phosphoserine at the Z-disk/I-band
junction of titin (P-S2080) showed unaltered phosphorylation,
as did P-S12742 in the PEVK domain (which is P-S11878 in
humans). We also used the anti-P-S3991 antibody for immunos-
taining on tissue sections and found regularly spaced doublet
lines for N2BusP-S3991 signals in WT co-localizing with PEVK,
but low-intensity N2BusP-S3991 signals in PP5 TG (Fig. 4e). On
immunoelectron micrographs, most nanogold particles indicative
of N2BusP-S3991 were found at the I-band springs in WT, whereas
only a small number was at the I-bands in PP5 TG hearts
(Fig. 4f). These data led us to conclude that, in vivo,
PP5 specifically dephosphorylates phosphoserines of titin located
in the N2Bus region.
PP5 transgenic cardiomyocytes have increased passive tension.
Passive force (Fpassive) measurements were performed on skinned
single cardiomyocytes of WT and PP5 TG mouse hearts in
relaxing buffer. Cell stretch over the range 1.8–2.4 µm SL resulted
in the typical, quasi-exponential increase in Fpassive (Fig. 5a).
Importantly, the Fpassive–SL curves were much steeper in PP5 TG
than in WT cardiomyocytes, and mean Fpassive was significantly
increased at SL ≥ 2.0 µm (Fig. 5b, c). When PP5 TG and WT
cardiomyocytes were incubated with recombinant PP5c, WT cells
showed an additional increase in Fpassive, whereas TG cells were
not altered in their stiffness (Fig. 5b). Moreover, Fpassive could be
reduced significantly in both WT and PP5 TG cardiomyocytes
upon treatment with ERK2 (Fig. 5c, d), PKA catalytic subunit
(Supplementary Fig. 3a), or cGMP-activated PKG (Supplemen-
tary Fig. 3b, c). In the presence of exogenous kinase, Fpassive was
always lower in WT than in TG cells. Finally, incubation of WT
myocytes with recombinant PP5c following treatment with ERK2
or PKG (and washout of the kinase) significantly increased Fpassive
to a level well above that measured in untreated WT cells (Fig. 5d
and Supplementary Fig. 3c). We conclude that PP5 is an
antagonist to the various PKs that phosphorylate N2Bus, in terms
of its effect on cardiomyocyte Fpassive.
PP5 and N2Bus bind to components of an I-band mechan-
osensor. N2Bus interacts directly with small heat-shock pro-
teins32 and FHL proteins, which on their part recruit metabolic
enzymes (FHL-231) and the MAPKs Raf1, MEK1/2 and ERK2
(FHL-129) to N2Bus, thus forming a putative mechanosensor
complex. We studied by GST-pulldown assay whether PP5 also
interacts with FHL-1 and found binding with both full-length
PP5 and PP5c (Fig. 6a, top). In cardiomyocytes, FHL-1 mainly
localized to the sarcomeric I-bands (marked by PEVK antibody)
and thus, at the expected N2Bus binding site (Supplementary
Fig. 4a). There was no difference in FHL-1 localization between
PP5 TG and WT hearts. Additional in vitro binding assays
revealed that PP5 or PP5c also interacted with ERK2 and Hsp90
(Fig. 6a), both of which have previously been described as binding
partners of PP528,36. Since PP1 and PP2a are important phos-
phatases in cardiomyocytes, we determined their expression
levels, as well as that of ERK2, in PP5 TG vs. WT mouse hearts,
but observed no differences (Supplementary Fig. 4b).
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Focusing on interactors of N2Bus, we confirmed binding of
this titin region to FHL-129 and FHL-231 by GST-pulldown
assay (Fig. 6b). FHL-2 also binds ERK237 and could thus play a
role in the N2Bus-associated mechanosensor. Interestingly,
N2Bus interacted in vitro with the α and β isoforms of Hsp90
(Fig. 6b). Since Hsp90 activates PP5 through binding to the TPR
region of the phosphatase, we performed in vitro ‘competition’
assays to test the impact of Hsp90 on the N2Bus-PP5
association. In these assays, pre-incubation of N2Bus-bound
sepharose beads with PP5, followed by incubation with Hsp90,
resulted in relatively weak binding of PP5 to N2Bus, whereas
pre-incubation of N2Bus-bound sepharose beads with Hsp90,
followed by incubation with PP5, resulted in significantly
stronger binding of PP5 to N2Bus (Fig. 6c). Thus, binding of
Hsp90 to N2Bus could promote subsequent PP5 binding to
N2Bus. In this context, we immunostained against Hsp90 on
myocardial tissue sections from PP5 TG and WT mice and
found a diffuse cytosolic distribution of the chaperone in WT,
with only an occasional hint at a more regular (sarcomeric)
striation pattern (Fig. 6d). However, in PP5 TG hearts, Hsp90
consistently showed a regular striation pattern, in addition to
the cytosolic localization, and co-localization with PEVK
suggested binding to I-band titin, presumably N2Bus (Fig. 6d).
Thus, Hsp90 and PP5 (Fig. 4c) may translocate to N2Bus in a
coordinated manner. In conclusion, we confirmed known binary
interactions within the N2Bus-associated mechanosensor and
provided evidence for additional interactions involving PP5 and
some of its binding partners.
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and TG hearts by immunogold electron microscopy. Bars, 500 nm. Bar graph shows average number of gold particles counted in 50-µm2-sized regions-of-
interest (ROI), either on the sarcomeric I-band or elsewhere in the cardiomyocyte (‘Not on I-band’). Data are mean± s.e.m., n= 5 ROIs from 2 hearts/
group. c PP5 localization in cardiomyocytes from PP5 TG and WT mouse hearts by indirect immunofluorescence. PP5 antibody (secondary antibody: Cy3-
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overexpression specifically decreases titin phosphorylation at N2Bus in PP5 TG vs. WT hearts. Total titin phosphorylation measured by ProQ Diamond/
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Bars, 2 µm (main) and 1 µm (insets). f Sarcomeric localization of phospho-N2BusP-S3991 in PP5 WT and TG hearts by immunogold electron microscopy.
Bars, 500 nm (main) and 100 nm (insets). Bar graph shows average number of gold particles counted in 50-µm2-sized regions-of-interest (ROI), either on
the sarcomeric I-band or elsewhere in the cardiomyocyte (‘Not on I-band’). Data are mean± s.e.m., n= 5 ROIs from 2 hearts/group. In a and d, bar graphs
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FHL-1-deficient hearts show reduced N2Bus phosphorylation.
In vitro data suggested that FHL-1 blocks ERK2-mediated
phosphorylation of specific N2Bus residues, including S399114.
However, FHL-1 may also promote N2Bus phosphorylation,
because FHL-1 is needed to anchor MAPKs at N2Bus29. To
address this conundrum, we quantified cardiac titin phosphor-
ylation in a mouse model deficient in FHL-129. Total phospho-
titin was significantly lowered by ~30%, whereas N2Bus phos-
phorylation at S3991 was reduced by ~50% in FHL-1 knockout
(KO) vs. WT hearts (Fig. 7a). As a control, we measured phos-
phorylation of S2080 at the Z-/I-band junction of titin and found
no difference between WT and FHL-1 KO (Fig. 7a). On immu-
nofluorescently stained tissue sections of both WT and FHL-1
KO hearts, PP5 appeared mainly in the cytosolic space and
sometimes at the sarcomeres; a difference in PP5-staining
intensity and pattern was not consistently observed (Fig. 7b).
Anti-P-S3991 antibody marked WT cardiomyocytes in a regular
striated (doublet) pattern and at relatively high intensities, over-
laying with PEVK, whereas FHL-1 KO cardiomyocytes con-
sistently showed very low anti-N2BusP-S3991 staining intensity
(Fig. 7c). In contrast, anti-P-S2080 antibody gave intense striation
patterns in both WT and FHL-1 KO cardiomyocytes (Fig. 7d).
On immunoelectron micrographs, N2BusP-S3991 nanogold parti-
cles localized abundantly to the sarcomeric I-band springs in WT
but were nearly absent from FHL-1 KO cardiomyocytes (Fig. 7e),
whereas anti-P-S2080 antibody again marked the Z/I titin region
similarly in both WT and FHL-1 KO (Fig. 7f). These findings
show that FHL-1 does not block phosphorylation of N2Bus
in vivo (at least at ERK2/PKA-dependent P-S3991) and suggest
that FHL-1 supports phosphorylation specifically at N2Bus sites
(but not I-band titin in general), presumably by targeting PKs to
this spring element.
Discussion
Unlike the phosphatases PP1, PP2a, and PP2b (calcineurin)2,38,
PP5 has gained little attention in the cardiac field, although it is
readily expressed in cardiomyocytes. A reason may be the low
basal activity of PP5 brought about by autoinhibition18,19.
However, PP5 is activated when Hsp90, Ca2+/S100 proteins,
arachidonic acid or LCACE bind to the enzyme (Fig. 8), to release
the autoinhibitory mechanism20–23. Our work now demonstrates
an important role for this distinctly regulated phosphatase in
cardiomyocytes, in that it binds and specifically dephosphorylates
the N2Bus spring element in cardiac titin, thus acting antagonistic
to the PKs that phosphorylate N2Bus and lower cardiomyocyte
passive tension. PP5 performs this function as a novel constituent
of the sarcomeric mechanosensor formed by N2Bus, FHL-1, and
the MAPK family members Raf1, MEK1/2, and ERK229. Unlike
proposed earlier14, FHL-1 does not block ERK2-mediated N2Bus
phosphorylation in this complex structure, as demonstrated by us
using WT and FHL-1 KO mouse hearts. Instead, FHL-1 supports
efficient phosphorylation of specific serines in N2Bus, probably
because it is important for the recruitment of MAPKs29 (and
perhaps other kinases) to N2Bus.
One effect of PP5 on the N2Bus-associated mechanosensor
complex is brought about by dephosphorylation of Raf1, which
blocks downstream MAPK signaling27. ERK2 cannot shuttle to
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the nucleus of the cardiomyocyte where it normally acts as a
transcriptional co-factor39 and mechanosensor function will be
compromised (Fig. 8). In support of this scenario, Raf1 activity
was reduced in the cardiomyocytes of PP5-overexpressing TG
mice (Fig. 4a). Another effect of PP5 on the mechanosensor is
triggered by the dephosphorylation of N2Bus. In PP5 TG hearts,
we found lowered site-specific N2Bus phosphorylation and
increased cardiomyocyte passive tension, compared to WT. Since
the rise in passive tension follows from reduced distensibility of
N2Bus due to the hypo-phosphorylation13, and considering that
mechanosensor function will depend on N2Bus distensibility29,
PP5 may inactivate the mechanosensor by stiffening N2Bus
(Fig. 8). Taken together, PP5-mediated regulation of mechan-
osensor activity is possible, in principle, by dephosphorylation of
Raf1 or N2Bus, or both.
MAPK/ERK signaling via Gαq is promoted by G-protein
coupled receptor (GPCR) agonists, such as ET-1 or AngII, in
cardiomyocyte cultures and intact hearts (Fig. 8)39–42. Our results
suggest that PP5 interferes with this pathway under physiological
conditions in cardiomyocytes and regulates it in a compartmen-
talized manner. In cultured NRVM, we observed ERK1/2 acti-
vation by AngII or ET-1, hyper-activation of ERK1/2 in the
presence of PP5-inhibitor okadaic acid, and very effective sup-
pression of ERK activity by PP5-activator arachidonic acid
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immunofluorescence. Anti-PP5, anti-N2BusP-S3991 or anti-Z/I-junctionP-S2080 (secondary antibody: Cy3-conjugated IgG), counterstained with anti-PEVK
antibody (secondary antibody: FITC-conjugated IgG). Bars, 5 µm (main) and 1 µm (insets). e, f Sarcomeric localization of phospho-N2BusP-S3991 (e) and
phospho-Z/I-junctionP-S2080 (f) in FHL-1 WT and KO hearts by immunogold electron microscopy. Bars, 500 nm (main) and 100 nm (insets). Bar graph in e
and f shows average number of gold particles counted in 50-µm2-sized regions-of-interest (ROI), either on the sarcomeric I-band or elsewhere in the
cardiomyocyte (‘Not on I-band’). Data in e and f are mean± s.e.m., n= 5 ROIs from two hearts/group. In a and e, *p< 0.05 and ***p< 0.001, by two-tailed
Student’s t-test
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02483-3 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:262 |DOI: 10.1038/s41467-017-02483-3 |www.nature.com/naturecommunications 9
(Supplementary Fig. 1). Cardiomyocytes treated with aa revealed
enhanced sarcomeric I-band association of PP5 (Fig. 2), which
could be the reason why the phosphatase appeared to have an
increased half-life when activated (as indicated by elevated pro-
tein expression). Cardiomyocyte-restricted induction of PP5 in a
TG mouse model also caused translocation of PP5 to the sarco-
meres, specifically to the position of N2Bus (Fig. 4). Although the
exact mechanism behind this translocation remains to be eluci-
dated, our work suggested potential triggers. First, we found that
phosphorylation of N2Bus enhanced PP5 binding to N2Bus
in vitro, and the effect was partially suppressed by mutating a
phosphoserine in N2Bus to alanine (Fig. 1d, e), suggesting the
added negative charge at N2Bus was the reason for the increased
PP5 affinity. Second, we found that PP5-activator Hsp90 trans-
located to the N2Bus region in PP5-overexpressing cardiomyo-
cytes (Fig. 6d), just as did PP5. Because Hsp90 promoted PP5
binding to N2Bus in vitro (Fig. 6c) and itself interacted with
N2Bus (Fig. 6b), the translocation of PP5 to N2Bus might be
guided by Hsp90. In this context, it may be of relevance that the
N2Bus binding site on PP5 is located not in the TPR region, but
at the beginning of the catalytic subunit (Fig. 1a, b). Hsp90 can
thus dock to the TPR region and activate PP5, while the phos-
phatase interacts with N2Bus. In summary, activated PP5 likely
performs its physiological functions in cardiomyocytes, including
the regulation of Gαq-mediated MAPK/ERK signaling, within a
defined compartment at the sarcomeric I-bands (Fig. 8).
Recruitment of PP5 to this compartment is promoted by stimu-
lation via Hsp90 or aa (perhaps also Ca2+/S100 and LCACE) and
through phosphorylation of N2Bus.
Elevated PP5 expression was observed in end-stage failing
human hearts and hypertensive dog hearts with diastolic
dysfunction (Fig. 3f and Supplementary Fig. 2b). Pathological
triggers could thus activate and recruit PP5 to the sarcomeric
N2Bus-FHL-MAPK complex in heart disease. In the failing
human and dog hearts, we confirmed the reduced site-specific
titin phosphorylation at N2Bus, but not PEVK (Fig. 3e and
Supplementary Fig. 2a), reported earlier34,35,43. Such phosphor-
ylation deficit at N2Bus is discussed as a main reason for the
pathological increase in titin-based myocardial passive stiffness in
HF, especially in HFpEF3,13,44. Whereas hypo-phosphorylation of
N2Bus in HFpEF has so far been explained mainly in terms of
pathologically downregulated cGMP-PKG signaling3,45, our
findings suggest another mechanism, which involves PP5. The
phosphatase most efficiently dephosphorylated ERK2-
phosphorylated human N2Bus in vitro, but also depho-
sphorylated PKA- or PKG-phosphorylated N2Bus (Fig. 3).
Moreover, recombinant PP5c reversed the softening effect of
ERK2 or cGMP-activated PKG on isolated skinned cardiomyo-
cytes (Fig. 5d and Supplementary Fig. 3c). In PP5 TG mouse
cardiomyocytes, ERK2/PKA-dependent N2Bus phosphosite P-
S3991 was much less phosphorylated than in WT, as was
CaMKIIδ-dependent P-S4043 and PKG-dependent P-S4080, but
not PKCα-dependent P-S12742 in the PEVK domain or P-S2080
at the Z/I junction of titin (Fig. 4). Thus, the induction of PP5 in
failing hearts and the activity of PP5 towards N2Bus (Fig. 3e) can
explain why there is a phosphorylation deficit specifically at
N2Bus but not at the PEVK domain34,35,46,47.
These findings implicate several potential treatment strategies
to reduce the high myocardial passive stiffness of HFpEF
patients44, which are worthwhile to be tested. First, the inhibition
of PP5 could increase N2Bus phosphorylation and lower titin-
based myocardial passive stiffness. Second, PP5 can associate with
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PP2a, either directly48 or indirectly through a regulatory subunit
that binds both phosphatases49. PP2a is known to depho-
sphorylate multiple cardiomyocyte proteins38,50 and it has been
used experimentally to dephosphorylate titin in vitro13. Thus, one
can speculate that PP5 may recruit PP2a to the sarcomeric I-band
complex at N2Bus (Fig. 8), where these phosphatases could work
in concert to dephosphorylate myofilament proteins like titin. If
so, it will be interesting to test whether inhibition of PP2a benefits
titin properties in normal and failing hearts. Moreover, PP5 could
be linked structurally or functionally to other important phos-
phatases in cardiomyocytes, such as PP1 and calcineurin2,38,51,52,
which is a possibility worth studying in the future.
Finally, PP5 is strongly inhibited by spermine17, a natural
polyamine closely related to spermidine, which was recently
shown to protect aging rodent hearts from diastolic dysfunction
by softening the cardiac walls53. Importantly, the spermidine
effect appeared to be related, in part, to increased titin phos-
phorylation at N2Bus. If spermine was found to have the same
beneficial effects on the heart, an interesting potential therapeutic
option for HFpEF patients would be to increase N2Bus phos-
phorylation and reduce titin-based stiffness by oral supple-
mentation with this polyamine. Conversely, one can test
spermidine for possible inhibitory effects on PP5. These novel
approaches targeting PP5 should complement other efforts in
HFpEF research directed at promoting the PKs (such as PKG54)
that phosphorylate N2Bus and reduce cardiomyocyte passive
stiffness.
In summary, we demonstrated an important signaling role for
PP5 in cardiomyocytes, as the phosphatase binds and depho-
sphorylates the N2Bus region of titin, which affects cardiomyo-
cyte passive stiffness. PP5 also interacts with components of the
N2Bus-associated mechanosensor and blocks MAPK/ERK sig-
naling in this complex. This way, PP5 functions in confined
compartments at the sarcomeric I-bands. Reversing the induction
of PP5 in heart failure would promote titin phosphorylation and
help reduce pathologically increased diastolic stiffness.
Methods
Yeast-two-hybrid screens. To search for interactors of N2Bus we first used an
unbiased yeast-two hybrid binding assay, as described55. Human N2Bus titin
region serving as bait was cloned into the pGBKT7 vector and transferred into
yeast strain AH109 (Clontech). Human cardiac cDNA library (Clontech) serving as
prey resided in a pACT2 vector, which was transformed into yeast strain Y187
(Clontech) using electroporation. Mating and screening procedures were carried
out as described by the manufacturer (Clontech); 3-amino-1.2.4-triazol (70 mM)
was used to eliminate background growth on selective media. Diploid yeast clones
were let to grow on triple dropout plates. To exclude false-positive interactions,
colonies were further analyzed for active β-galactosidase using an X-Gal filter-lift
assay. Plasmids from blue-turned, positive clones were isolated and sequenced. A
BLAST analysis revealed possible binding partners of N2Bus. To verify interac-
tions, direct binding assays were performed in yeast with the potential binding
partner (in pACT2 and Y187) and N2Bus (in pGBKT7 and AH109). Resulting
diploid yeast clones from the small scale mating were analyzed by PCR for the
presence of both fragments.
Recombinant protein expression and GST-pulldown assays. Human recombi-
nant proteins were expressed as described32. Glutathione S-transferase (GST)
fusion proteins were constructed by fusing a protein of interest to GST in the
expression vector pGEX-4T-2 (Amersham) via EcoRI and XhoI. The expression of
GST-fusion proteins was induced in Escherichia coli strain XL1blue (Stratagene)
using 0.2 mmol/l isopropyl-β-D-thiogalactopyranoside (IPTG). The primers used
for protein expression are listed in Supplementary Table 1. Only FHL-1 (Abnova)
and ERK2 proteins (Abcam) were obtained from commercial sources. Purification
was carried out according to manufacturer’s instructions using glutathione
sepharose beads (GSH, Amersham). Free polypeptides were obtained after
thrombin cleavage (10 U) of GST-fusion proteins and spare thrombin was removed
by using para-aminobenzamidine sepharose beads (Sigma-Aldrich). Purified pro-
teins were used in multiple assays. Site-directed mutagenesis was used to generate
mutant constructs of N2Bus (C-terminus) and PP5c. In the wildtype C-terminal
N2Bus fragment (amino acids 411–572 of N2Bus) serine S4185 (referring to full-
length human titin; UniProtKB entry Q8WZ42), which is phosphorylated by
PKG and PKA13, was exchanged for an alanine (S4185A), using primer 5′-
GAATCCATTTCTTCTTGCAAAGCTGTTTTGGCTCC-3′. To obtain enzymatic
dead (ED) mutant PP5c, a histidine at position 304 was mutated to alanine
(H304A) via two-step-PCR using the following primers: 1st reaction: 5′(wildtype):
AAAAGAATTCACAGCATGACCATTGAGGAT, 3′(mutant):
GTCTGTCTCGGCGTTGCCT; 2nd reaction: 5′(product of 1st PCR reaction), 3′
(wildtype): TTTTCTCGAGCATCATTCCTAGCTGCAG.
GST-pulldown assays were conducted as described previously32. Briefly, a
specific purified protein was incubated with a GST-fusion protein immobilized on
glutathione sepharose beads at 4 °C for 1.5 h. Beads were then washed in high and
low salt buffer three to four times. Samples were collected from each washing step
including a sample of the beads. Analysis was performed by SDS-PAGE and
western blot. Mostly, anti-PP5 antibody (target, N-terminal of human PP5; Cell
Signaling, #2289; polyclonal, rabbit; 1:2000) or anti-PP5c (catalytic subunit)
antibody (target, rat PP5 amino acids 36–238; 3/PP5; BD Biosciences, 611021;
monoclonal, mouse; 1:2000) was used for detection, sometimes also anti-N2Bus
(titin) antibody (custom-made by Eurogentec; affinity-purified polyclonal, rabbit;
1:500)15,34 or anti-Hsp90(pan) antibody (target, peptide surrounding Asn300 of
human Hsp90; C45G5; Cell Signaling, #4877 S; monoclonal, rabbit; 1:1000). A
given interaction test was performed at least three times. Uncropped images of gels
and western blots are shown in Supplementary Fig. 5 and Supplementary Fig. 6.
Co-immunoprecipitation assay. Prior to transfection, 1 × 105 HEK cells were
seeded in 24-well plates and incubated at 37 °C and 5% CO2 for 24 h. Cells were
transfected (calcium phosphate method) using HA-tagged PP5 (3 µg DNA/well)
and myc-tagged N2Bus (2 µg DNA/well). As DNA vector backbones we used
pcDNA 3.1 (for PP5) and pCMV-Myc (for N2Bus). Twenty 4 h after transfection
cells were rinsed twice with phosphate-buffered saline (PBS) and lysed by addition
of 60 µl CellLytic M Reagent (Sigma-Aldrich) per well. PP5-HA was coupled to 20
µl anti-HA agarose beads in spin columns (Pierce HA tag IP/CoIP Kit, Thermo-
Fisher Scientific) at 4 °C and 4 rpm overnight. Beads were spun down briefly and
N2Bus-myc containing whole-cell lysate was added for 6 h at 4 °C and 4 rpm. After
10 s of pulse centrifugation the flow-through was discarded, beads were washed
with PBS (3x) and bound protein eluted by addition of 100 µl non-reducing sample
buffer at 95 °C for 5 min. Fractions were loaded on 10% SDS-PAGE gels at equal
proportions; however, the eluate was additionally loaded at 7.5-fold excess, to
reproducibly detect interaction). For western blotting, polyvinylidene difluoride
(PVDF) membrane was blocked using 3% bovine serum albumin (BSA) at room
temperature for 1 h. Primary antibodies were incubated at 4 °C overnight, sec-
ondary antibody at room temperature for 1 h. Signal detection of HRP conjugates
was enhanced by ECL Western Blotting Detection kit (GE Healthcare). The fol-
lowing antibodies were used: anti-HA (target, HA peptide sequence (amino acids
76–111) of ×47 hemagglutinin; 3F10; Roche, #11867423001; monoclonal, rat;
1:4000) or anti-myc (target, aa 410–419 of human c-Myc; 9E10; Abcam, #ab32;
monoclonal, mouse; 1:2000) as primary antibodies and anti-rat HRP (Dianova,
#112-035-003; polyclonal, goat; 1:15,000) or anti-mouse HRP (Dianova, #115-035-
003; polyclonal, goat; 1:10,000) as secondary antibodies.
Immunofluorescence labeling of stretched single myofibrils. Single myofibrils
were isolated from human donor hearts (left ventricular tissue) and stretched in a
custom-made setup, as described32. Briefly, single myofibrils were glued under an
inverted microscope (Axiovert 135; Zeiss, Jena) to the tips of two microneedles, one
connected to a rigid post, the other to a micromanipulator. Samples were rinsed in
relaxing buffer (1 mmol/l of free Mg, 100 mmol/l KCl, 2 mmol/l EGTA, 4 mmol/l
Mg-ATP, and 10 mmol/l imidazole, pH 7.0) at room temperature. Myofibrils were
stretched and incubated for 20 min with recombinantly expressed catalytic subunit
of PP5 (PP5c, 12 U/µl; activity measured using SensoLyte pNPP Protein Phos-
phatase Assay Kit (Anaspec)). Other myofibrils were pretreated for 30 min with
PKA (recombinant catalytic subunit, 1 U/μl, Biaffin) before the incubation with
PP5c. After 3 washing steps using relaxing buffer, bound PP5c was visualized by
indirect immunofluorescence using primary anti-PP5c antibody (target, rat PP5
amino acids 36–238; 3/PP5; BD Biosciences, 611021; monoclonal, mouse; 1:50) and
secondary Cy3-conjugated IgG (target, gamma immunoglobins heavy and light
chains; Invitrogen, #A10520; polyclonal, goat; 1:400).
Healthy and failing heart muscle tissues. Left ventricular (LV) samples of non-
failing human hearts were from brain-dead donors with normal LV function.
Failing heart samples were from patients with dilated cardiomyopathy (DCM) who
underwent heart transplantation due to severe systolic dysfunction (NYHA class III
or IV). Sample collection was done in full accordance with Australian National
Health Medical Research guidelines and approved by the Human Research Ethics
Committee of the University of Sydney (HREC approval: 2012/2814). Informed
consent was obtained from the next of kin of all organ donors. It is a requirement
of the University of Sydney Human Research Ethics Committee that the consents
not only must be sighted before the heart can be included in the Sydney Heart
Bank54, but any identifying details be redacted. Healthy dog heart tissue was
obtained from adult mongrels (8–12 years) and failing heart samples from adult
mongrel dogs made hypertensive by bilateral renal wrapping55. All dog samples
were collected at the Mayo Clinic (Rochester, Minnesota, USA) in full accordance
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with the institutional guidelines and approved by the Mayo Clinic Ethics Com-
mittee. Fetal (E18), newborn (P1) and adult heart tissue was obtained from female
Wistar-Kyoto rats, following the guidelines and under the approval of the Animal
Care and Use Committee at Ruhr University Bochum, Germany.
PP5-overexpressing transgenic mouse hearts. PP5 TG mice (CD1 strain) with
cardiomyocyte-specific overexpression of the phosphatase under the α-myosin
heavy-chain promoter were generated as described previously25. The transgene
consisted of the α-myosin heavy-chain promoter, the entire protein coding region
for rat PP5 (plus 483 base pairs of 3′ untranslated sequence), and the SV40
polyadenylation signal sequence. The transgene, isolated from the parent plasmid,
was microinjected in fertilized mouse eggs. Mice positive for the transgene were
identified via Southern blot and PCR of tail genomic DNA. In total, we studied the
hearts of four TG and four litter-matched WT male mice aged 5–6 months, using a
TG line with 7–8-fold overexpression of the phosphatase. These PP5 TG hearts
showed a slightly compromised contractility in a previous study that provided
phenotypic characterization of the model25. Hearts from TG and WT animals were
collected at University of Muenster in full accordance with the institutional
guidelines. Approval for the study was granted by the State Office for Nature,
Environment and Consumer Protection North Rhine-Westphalia (LANUV NRW;
reference number 8.87-50.10.36.09.006). Samples were prepared for immediate
mechanical measurements of isolated cardiomyocytes, immunofluorescence, and
immunoelectron microscopy, or deep-frozen for later biochemical analysis.
FHL-1 knockout mouse hearts. A mouse model deficient in FHL-1 (kind gift from
Dr. Ju Chen, University of California-San Diego, La Jolla, CA, USA) was generated
previously29. From this model we obtained adult heart tissue (6–8-month-old male
mice) and analyzed three KO and three litter-matched WT hearts. All animal
procedures were in full compliance with the guidelines approved by the UCSD
Animal Care and Use Committee. The committee approved the procedure of heart
extraction from the deceased animals for later biochemical and histochemical
analysis.
Neonatal rat cardiomyocyte cultures. NRVM were isolated and prepared from 1-
day-old to 2-day-old Wistar-Kyoto rat hearts56, following the guidelines and under
the approval of the Animal Care and Use Committee at Ruhr University Bochum.
Cells were dispersed by incubation in pancreatin solution containing 8 g NaCl, 2 g D-
glucose, 200mg KCl, 57.5 mg NaH2PO4-H2O, 20mg phenol red, 1 g Na-bicarbonate,
supplemented with 20mg pancreatin (Sigma-Aldrich) and 150U collagenase
(Roche) per 100ml at 37 °C. After several digestion steps, the pellet was suspended in
Dulbecco’s modified Eagle medium with 10% fetal calf serum (FCS) and antibiotics
(10mg/ml penicillin/streptomycin; Gibco). Pre-plating for 1 h removed unattached
cells and fibroblasts and increased the content of cardiomyocytes. The cell suspen-
sion was then plated at a density of 1 × 106 cells/mm2 and cultured at 37 °C and 5%
CO2. After 24 h, medium was replaced by fresh culture medium. Following another
2 h, some cells were treated with arachidonic acid (aa; Sigma-Aldrich; 200 µM, 2 h)
or okadaic acid (oa; Sigma-Aldrich; 10 nM, 1 h), while others were left untreated
(‘control’). Additional cells were treated with inhibitor of Raf1 (cRaf1-I GW5074;
Enzo Lifesciences; 20 µM; 1 h) or, to stimulate the MAPK pathway, with angiotensin-
II (AngII; Sigma-Aldrich; 1 µM; 24 h), endothelin-1 (ET-1; Sigma-Aldrich; 10 nM;
24 h), or a combination of those. Cells were rinsed with warm PBS and subsequently
harvested in 1.5 ml fresh PBS. After centrifugation, pellets were resolved in 40 µl
modified Laemmli buffer (8M urea; 2M thiourea; 3 % SDS; 50mM Tris-HCl
(pH 6.8); 10% glycerol; 75mM DTT; Serva Blue) and analyzed by SDS-PAGE and
western blot for expression of PP5, ERK1/2, Phospho-ERK1/2, and GAPDH (loading
control), using the following antibodies: anti-PP5 (target, N-terminal of human PP5;
Cell Signaling, #2289; polyclonal, rabbit; 1:2000), anti-ERK1/2 (target, peptide cor-
responding to a sequence in the C-terminus of rat p44 MAP Kinase; Cell Signaling,
#9102; polyclonal, rabbit; 1:1000), anti-P-ERK1/2 (target, phosphopeptide corre-
sponding to residues surrounding Thr202/Tyr204 of ERK/MAPK; Biaffin, #AB-pERK-
100; polyclonal, rabbit; 1:1000), and anti-GAPDH (target, full-length protein cor-
responding to human GAPDH; Abcam, #ab9484; monoclonal, mouse; 1:2000).
P-ERK1/2 expression was normalized to ERK1/2 expression, indexed to GAPDH.
Cells were prepared for indirect immunofluorescence and stained using antibodies
against PP5 (target, N-terminal of human PP5; Cell Signaling, #2289; polyclonal,
rabbit; 1:50), Z-disk marker α-actinin (target, rabbit skeletal α-actinin; EA-53; Sigma-
Aldrich, #A7811; monoclonal, mouse; 1:300), and with Hoechst (ThermoFisher
Scientific) to visualize the nuclei. Confocal laser scanning microscopy was done using
the Nikon Eclipse Ti microscope.
Adult rat cardiomyocyte cultures. ARC were prepared as described32. Briefly,
Wistar-Kyoto rats were euthanized with isoflurane, following the guidelines and
under the approval of the local Animal Care and Use Committee. The abdomen
was opened and ice-cold perfusion buffer (PB) with heparin was injected. The heart
was excised and mounted on the cannula of a Langendorff perfusion system.
Enzymatic digestion and rinsing were performed with different buffers in the cell
isolation process, as described32. Cells were incubated in medium supplemented
with 4% FCS, ITS (insulin/transferrin/selenium) and butanedione monoxime
(BDM; 10 mM). Shortly after plating, this medium was exchanged for serum-free
medium (M199, Invitrogen; +ITS, +10 mM BDM). Ventricular cardiomyocytes
were used for experiments from day 2 onwards. Cells were treated with arachidonic
acid (aa, 200 µM; 2 h), or okadaic acid (oa, 10 nM; 1 h), while other cells were left
untreated (‘control’). Cells were then harvested as described above for NRVM.
Total titin phosphorylation was detected on titin gels stained with the ProQ Dia-
mond (phosphoprotein) vs. Sypro Ruby (total protein) system. Other cells were
immunostained using antibodies against PP5 (target, N-terminal of human PP5;
Cell Signaling, #2289; polyclonal, rabbit; 1:50) and α-actinin, (target, rabbit skeletal
α-actinin; EA-53; Sigma-Aldrich, #A7811; monoclonal, mouse; 1:300) or phospho-
N2BusS3991 (custom-made by Eurogentec; affinity-purified polyclonal, rabbit;
1:400)15,34 and α-actinin, and indirect immunofluorescence was again performed
using confocal laser scanning microscopy. On those samples, we counted the
proportion of cells showing a clear striation pattern for either PP5 or titin P-S3991,
relative to the total number of cells. Counting was done by a person blinded to the
identity of the cells.
Immunofluorescence microscopy. Cultured cardiomyocytes or heart tissue sec-
tions were fixed in 4% paraformaldehyde (PFA) for 20 min, rinsed with PBS, and
permeabilized with 0.5% triton X-100 for 5 min. After repeated washes with PBS,
samples were blocked with 2% BSA for 20 min and subsequently stained with
primary antibodies for 1 h at room temperature as follows: anti-α-actinin (target,
rabbit skeletal α-actinin; EA-53; Sigma-Aldrich, #A7811; monoclonal, mouse;
1:300), anti-PP5 (target, N-terminal of human PP5; Cell Signaling, #2289; poly-
clonal, rabbit; 1:50), anti-PEVK-titin (custom-made by Eurogentec; affinity-
purified polyclonal, rabbit; 1:40)15,34, anti-phospho-N2Bus of titin (P-S3991;
custom-made by Eurogentec; affinity-purified polyclonal, rabbit; 1:400)15,34, anti-
FHL-1 (target, immunogen corresponding to amino acids 23–121 of human FHL-
1; Abcam, #ab58067; monoclonal, mouse; 1:250), anti-Hsp90 (target, peptide
surrounding Asn300 of human Hsp90; C45G5; Cell Signaling, #4877S; monoclonal,
rabbit; 1:20) and anti-phospho-Z/I-region of titin (P-S2080, custom-made by
Eurogentec; affinity-purified polyclonal, rabbit; 1:100). Secondary antibodies for
immunofluorescence were incubated for 1 h at room temperature at the following
concentrations: Cy3-conjugated IgG (target, gamma immunoglobins heavy and
light chains; Invitrogen, #A10520; polyclonal, goat), 1:300, and FITC-conjugated
IgG (target, mouse IgG whole molecule; Rockland, #210–1204; polyclonal, goat),
1:200. In control experiments, secondary antibody alone was used, but did not
reveal any immunofluorescence signals above background. Immunostained sam-
ples were embedded in Mowiol (Sigma-Aldrich) and analyzed by confocal laser
scanning microscopy (Nikon Eclipse Ti microscope). Immunofluorescence imaging
was processed similarly in the experimental and control groups.
Immunoelectron microscopy. PP5 TG, FHL-1 KO mouse hearts, and matching
WT hearts were fixed in 4% PFA, 15% saturated picric acid in 0.1 M phosphate
buffer (pH 7.4) overnight at 4 °C and cut into longitudinal sections on a vibratome
(Leica VT 1000 S). Thin sections were blocked in 20% normal goat serum (NGS)
and incubated with primary antibodies in PBS supplemented with 5% NGS
overnight at 4 °C. The following antibodies were used: anti-PP5 (target, N-terminal
of human PP5; Cell Signaling, #2289; polyclonal, rabbit; 1:50), anti-P-S3991 of
N2Bus-titin (custom-made by Eurogentec; affinity-purified polyclonal, rabbit;
1:400)15,34, or anti-P-S2080 of Z/I-region of titin (P-S2080, custom-made by
Eurogentec; affinity-purified polyclonal, rabbit; 1:100). Sections were rinsed and
incubated with 1.4 nm gold-coupled secondary antibodies (Nanoprobes, Stony
Brook, NY, USA) overnight at 4 °C. After extensive washing, sections were post-
fixed in 1% glutaraldehyde for 10 min and then reacted with HQ Silver kit
(Nanoprobes). OsO4 and uranyl acetate were used for counterstaining. After
dehydration via ascending ethanol series, the samples were embedded in Durcupan
resin (Fluka, Switzerland). Ultrathin sections (Ultracut S, Leica, Germany) were
prepared and analyzed using a Zeiss LEO 910 electron microscope. For quantifi-
cation of results, the nanogold particles were counted on 50 µm2-sized regions-of-
interest, distinguishing the particles bound to titin in the sarcomeric I-band (‘On I-
band’) vs. those located elsewhere in the cardiomyocyte (‘Not on I-band’). The
counting person was blinded to genotype/phenotype.
SDS-PAGE and immunoblotting. Deep-frozen cardiac tissues (or cardiomyocyte
cultures) were homogenized in modified Laemmli buffer, stored on ice for 30 min
and subsequently boiled for 3 min at 97 °C. Protein concentration was determined
spectrophotometrically using the method of Neuhoff57. Standard SDS-PAGE was
employed for proteins of ‘normal’ size and agarose-strengthened 2% SDS-PAGE
for titin analysis58. Western blotting was performed as described59. Antibodies to
the following proteins were used: PP5 (target, N-terminal of human PP5; Cell
Signaling, #2289; polyclonal, rabbit; 1:2000), PP5c (target, rat PP5 amino acids
36–238; 3/PP5; BD Biosciences, 611021; monoclonal, mouse; 1:2000), GAPDH
(target, full-length protein corresponding to human GAPDH; Abcam, #ab9484;
monoclonal, mouse; 1:2000), PP1α (target, peptide corresponding to the N-
terminal sequence of human PP1α; Cell Signaling, #2582; polyclonal, rabbit;
1:1000), PP2a (α + β isoform; target, peptide corresponding to amino acids at the
C-terminus of human PP2A catalytic subunit; Cell Signaling, #2038; polyclonal,
rabbit; 1:1000), phospho-Raf1 (Ser338; target, phosphopeptide corresponding to
residues 333–345 of human Raf-1; Merck, 05–538; monoclonal, mouse; 1:1000),
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02483-3
12 NATURE COMMUNICATIONS |  (2018) 9:262 |DOI: 10.1038/s41467-017-02483-3 |www.nature.com/naturecommunications
Hsp90 (target, peptide surrounding Asn300 of human Hsp90; C45G5; Cell Sig-
naling, #4877S; monoclonal, rabbit; 1:1000), ERK1/2 (target, peptide corresponding
to a sequence in the C-terminus of rat p44 MAP kinase; Cell Signaling, #9102;
polyclonal, rabbit; 1:1000) and phospho-ERK1/2 (target, phosphopeptide corre-
sponding to residues surrounding Thr202/Tyr204 of ERK/MAPK; Biaffin, #AB-
pERK-100; polyclonal, rabbit; 1:1000).
Quantification of titin phosphorylation. By 32P-autoradiography we measured
phosphorylation of recombinant human N2Bus15. N2Bus fragment was incubated with
PKG (4.7 U/µl + 10mM cGMP; kindly provided by Dr. Elke Butt, Würzburg, Ger-
many) or PKA catalytic subunit (1 U/μl; Biaffin) in presence of [γ32P]ATP (250 µCi/
µM; Hartmann Analytic, Braunschweig, Germany) for 30min at 35 °C. Some samples
were dephosphorylated overnight at 35 °C with recombinant full-length PP5 or catalytic
subunit of PP5 (PP5c) (12U/µl). Samples were loaded on 7.5% SDS-PAGE gels, which
were dried and exposed to autoradiographic film (Fujifilm BAS-1800 II) overnight at
room temperature. Signals were analyzed using Multi Gauge V3.2 software.
The ProQ Diamond/Sypro Ruby dual staining system (Molecular Probes) was
used to measure titin phosphorylation in recombinant N2Bus, rat cardiomyocytes,
or adult mouse heart tissue. Recombinant human N2Bus was phosphorylated with
PKG (4.7 U/µl, plus 10 mM cGMP), PKA catalytic subunit (1 U/μl), or ERK2 (20.5
U/ml; ThermoFischer Scientific) in presence of ATP for 30 min at 35 °C, and was
dephosphorylated overnight at 35 °C using recombinant full-length PP5 or catalytic
subunit of PP5 (PP5c) (12 U/µl). A separate batch of recombinant N2Bus was also
treated (following phosphorylation) with enzymatic dead PP5c (ED H304A
mutant) overnight at 35 °C. Proteins were separated on SDS-PAGE gels stained
with ProQ Diamond for 1 h and subsequently with Sypro Ruby overnight. Proteins
were visualized using the LAS-4000 image reader (Fujifilm). Protein bands were
analyzed densitometrically and phospho-signals on ProQ Diamond-stained gels
were normalized to corresponding total protein signals on Sypro Ruby-stained gels.
By western blotting, we measured site-specific titin phosphorylation in heart
tissue, as described15,34. Following separation of titin on loose SDS-PAGE gels,
immunoblotting was performed using custom-made, affinity-purified, phospho-
specific antibodies against phosphoserines in titin (for details, see ref. 15). The
following anti-mouse titin antibodies (affinity-purified, polyclonal, rabbit),
generated by Eurogentec (Belgium), were used (amino acid positions according to
UniProtKB identifier, A2ASS6): anti-P-S2080 (Z/I-junctional region; 1:400); anti-
P-S3991 (1:400); -P-S4043 (1:400); -P-S4080 (1:400) (all N2Bus); and anti-P12742
(1:400) (PEVK domain)15,34. For each phosphosite-specific anti-mouse antibody, a
corresponding pan-titin antibody recognizing both the phosphorylated and the
non-phosphorylated site was used separately on western blots. For quantification of
phosphorylation, phospho-titin signals were normalized to signals obtained with
the corresponding pan-titin antibodies. Moreover, phospho-specific anti-human
titin (UniProtKB identifier, Q8WZ42) antibodies (affinity-purified, polyclonal,
rabbit) were used that have been generated by Eurogentec against P-S4010 (1:400),
P-S4099 (1:400) (both N2Bus), P-S11878 (1:400), and P-12022 (1:400) (both
PEVK)15,34. Another antibody (affinity-purified, polyclonal, rabbit) was custom-
made by Immunoglobe (Himmelstadt, Germany) against P-S4185 in human
N2Bus (1:500)34; this site is present in human titin, but is not cross-species
conserved13. Signals obtained with the anti-human antibodies were indexed to
signals on (coomassie-stained) PVDF blotting membrane, to adjust for differences
in protein load. In some experiments, endogenous titin in human heart samples
was first dephosphorylated using alkaline phosphatase (AP, 10 U/µl; New England
Biolabs) before back-phosphorylation with PKG, followed by dephosphorylation
with PP5 or PP5c. Uncropped images of gels, autoradiogrammes, and western blots
are shown in Supplementary Fig. 5 and Supplementary Fig. 6.
Force measurements on isolated skinned cardiomyocytes. Force measurements
were performed on single, isolated cardiomyocytes, as described15. Cardiomyocytes
were isolated from the hearts of PP5 TG (n = 3) and litter-matched WT (n = 3) mice.
Cells were skinned in relaxing buffer by using 0.5% Triton X-100 and placed under a
Zeiss Axiovert 135 inverted microscope (×40 objective). Single cardiomyocytes were
suspended between a force transducer and a motor, which are part of a ‘Permea-
bilized Myocyte Test System’ (1600A; Aurora Scientific, Aurora, Canada). Experi-
ments were performed in relaxing solution at room temperature. SL was set to slack
(1.8–1.9 µm SL) and then increased step-wise to 2.4 µm while the force was recorded.
‘Passive’ force values were normalized to myocyte cross-sectional area calculated
from the diameter of the cells, assuming a circular shape. In separate sets of
experiments, PP5 WT or TG cardiomyocytes in relaxing buffer were incubated with
one of the following enzymes: catalytic subunit of PP5 (PP5c, 12 U/µl, used at 0.6 µg/
µl), ERK2 (20.5 U/ml), PKG (0.1 U/ml) in presence of activator cGMP (10mM), or
PKA (catalytic subunit) (100 U/ml). Sometimes, the PP5 was added after prior
incubation with a kinase. Incubation time per enzyme was 40min at 20 °C. On
passive tension vs. SL plots, mean data points were fit by third-order polynomials.
Statistical analysis. Values are given as mean± s.e.m. of n observations in each
group; biological replicates are indicated. Means were compared using Bonferroni
adjusted t-test or two-tailed Student’s t-test, if data passed the normal distribution
test. For multiple comparisons, the Holm-Sidak method was applied. Data needed
to pass the equal variance test. Three levels of significance were defined: *p < 0.5;
**p< 0.01; and ***p < 0.001. Analyses were performed in GraphPad Prism 5 or
SigmaPlot 12.5.
Data availability. All relevant data are available from the authors upon reasonable
request.
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